Navigation Links
The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
Date:12/10/2013

SAN FRANCISCO, Dec. 10, 2013 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter will be hosting its annual Emerging Therapies & Survivorship Conference for blood cancer patients on Saturday, January 25, 2014, from 8:30 a.m. to 12:30 p.m. PT at the Hyatt Regency San Francisco.  The Emerging Therapies & Survivorship Conference is a free event that brings the latest advances in blood cancer research and clinical trials to Northern California blood cancer patients, caregivers and healthcare professionals.  LLS is honored to be hosting keynote speaker Dan Shapiro, Ph.D., psychologist, professor, author and professional speaker, to give his notable talk, A Funny Thing Happened on My Way to Chemotherapy.

The Emerging Therapies & Survivorship Conference will begin with breakfast and a welcome message from LLS, and continue with the keynote speech, exhibitor sessions and concurrent breakout sessions.  During the breakout sessions, attendees will have the opportunity to speak with hematology experts about various blood cancers, including acute myeloid leukemia, myelodysplastic syndromes, non-Hodgkin lymphoma, and more.  To view the complete conference program agenda, please click here.

Sponsors for the 2014 Emerging Therapies & Survivorship Conference include Millennium, Genentech, Onyx Pharmaceuticals, Celgene, and Gilead and partners include Association of Northern California Oncologists, Marin Specialty Care, Redwood Regional Medical Group, Stanford Cancer Center, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, and Sutter Medical Center of Santa Rosa.

The Emerging Therapies & Survivorship Conference is a free educational event and will be taking place on Saturday, January 25, 2014, from 8:30 a.m. to 12:30 p.m. PT at the Hyatt Regency San Francisco, located at 5 Embarcadero Center, San Francisco, Calif., 94111.  Space is limited and registration is required.  To reserve your space, register online at bit.ly/emergingtherapies

For more information about the conference, contact Lauren Wilkerson, MPH, MSW, at 415-625-1115 or visit www.lls.org/gba.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer.  The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.  LLS funds lifesaving blood cancer research around the world and provides free information and support services for patients and their loved ones.

Major LLS fundraising campaigns include Team In Training, Light The Night Walk, School & Youth, Man & Woman of the Year and Leukemia Cup Regatta.  To reach the widest possible audience, LLS partners with national and regional level companies and brands, including Nike, Disney, Burlington and others.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada.  To learn more, visit www.LLS.org.  Patients and caregivers should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.Greater Bay Area Chapter OfficesSan Francisco

221 Main Street, Suite 1650, San Francisco, CA 94105, 415-625-1100Silicon Valley/Monterey

675 North First Street, Suite 1100, San Jose, CA 95112, 408-490-2666North Bay

2455 Bennett Valley Road, Suite B204, Santa Rosa, CA 95404 707-544-4350


'/>"/>
SOURCE Leukemia & Lymphoma Society - Greater Bay Area Chapter
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
3. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
4. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
7. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
8. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
9. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
10. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
11. The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
Breaking Medicine Technology:
(Date:4/28/2016)... BROOKLINE, MA (PRWEB) , ... April 28, 2016 , ... ... his revolutionary work in the emerging field of biomechatronics, technology that marries human physiology ... the MIT Media Lab. He is also the Founder of BionX , a ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... 28, 2016 , ... One way to ignore solid evidence is to dismiss ... we toss the baby out with the bathwater when we ignore all studies because ... studies and otherwise making better use of education policy research. , “When readers heed ...
(Date:4/28/2016)... ... April 28, 2016 , ... USA Medical Card reminds us that May is National ... stroke is the fourth leading cause of death in the United States; someone has one ... quarter of them in individuals under 65 years old. A stroke is when blood ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
Breaking Medicine News(10 mins):